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Abstract
Background: The regulation and function of IgE in healthy individuals and in
antigen-naı¨ve animals is not well understood. IL-33 administration increases
serum IgE in mice with unknown mechanism. We tested the hypothesis that
IL-33 provides an antigen-independent stimulus for IgE production and mast cell
degranulation.
Methods: IL-33 was administered to naı¨ve wild-type (WT), nude and ST2/,
IL-4/, IL4Ra/ and T-or B-cell-specific IL-4Ra/ mice. IgEand cytokines
were quantified by ELISA. T- and B-lymphocyte numbers and CD40L expression
were determined by flow cytometry. Anaphylaxis was measured by temperature,
mast cell degranulation and histamine release.
Results: IL-33 enhanced IgE production in naı¨ve WT, T-IL-4Ra/ but not in
ST2/, IL-4/, IL-4Ra/ or B-cell-specific IL-4Ra/ mice, demonstrating
IL-33 specificity and IL-4 dependency. Moreover, IL-4 was required for IL-33-
induced B-cell proliferation and T-cell CD40L expression, which promotes IgE pro-
duction. IL-33-induced IL-4 production was mainly from innate cells including mast
cells and eosinophils. IL-33 increased mast cell surface IgE and triggered degranula-
tion and systemic anaphylaxis in allergen-naı¨ve WT but not in IL-4Ra/mice.
Conclusion: IL-33 amplifies IgE synthesis and triggers anaphylaxis in naı¨ve mice
via IL-4, independent of allergen. IL-33 may play an important role in nonatopic
allergy and idiopathic anaphylaxis.
IgE antibody is induced by allergen and requires immuno-
globulin heavy-chain class switching and affinity maturation
in B cells in a T-cell-dependent manner (1, 2). IgE is also pro-
duced naturally (1, 3) but less is known about the selective
amplification and function of natural IgE in healthy subjects
and antigen-naı¨ve animals (3). Natural IgE is secreted by B2
cells and contributes to the baseline concentrations of nonal-
lergen-specific IgE in the serum and tissues of healthy individ-
uals (3, 4). In contrast to allergen-induced IgE, cognate
T-helper cell via MHC class II and somatic hypermutation
are not required for the generation of natural IgE (3). Instead,
bystander stimulation from T-cell CD40L and low levels of
IL-4 are necessary (3, 4). The functions of natural IgE are
poorly understood; they are polyreactive and have a critical
role in immune priming (3–7). IgE can bind the high-affinity
IgE receptor (FceRI) and prolong mast cell survival, release a
spectrum of cytokines and have important roles in defence
against infection and initiation of adaptive immunity (5–8).
IL-33 is a new IL-1 family member and signals via a
receptor complex consisting of ST2 (IL-1LR1) and IL-1RAcP
(9, 10). IL-33 is expressed by innate cells in humans and
mice, primarily epithelium and endothelium, and can be
released when cells sense inflammatory signals or undergo
Abbreviations
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necrosis (9–11). ST2 is expressed by most innate cells but
only by selected adaptive immune cells (9, 12, 13). Thus,
IL-33 can directly activate eosinophils, basophils, macro-
phages and NK cells via ST2 (9, 14–16). In contrast, ST2 is
selectively expressed on IL-5+Th, Th2 but not Th1 or Th17
cells (17–19). While enhancing mature Th2-cell function,
IL-33 cannot polarize Th2 cells (17). Interestingly, IL-33 can
induce IgE production in naı¨ve mice (9). However, the effect
and mechanism by which IL-33 induces IgE production in
naı¨ve mice is largely unknown.
We aim to identify the mechanism and role of IL-33 in the
induction and regulation of IgE production in allergen-naı¨ve
mice. We report that IL-33 amplifies IgE synthesis via IL-4
from innate immune cells that is sufficient to trigger mast cell
degranulation and anaphylaxis in the absence of allergen.
Materials and methods
Mice
BALB/c, BALB/c nude and C57BL/6 mice were purchased
from Harlan Olac. ST2/ mice (20), IL-4/, IL-4 receptor a
chain knockout (IL-4Ra/) (21) and mice selectively defi-
cient in IL-4Ra on B cells (F. Brombacher, unpublished) or T
cells (LckcreIl4ra/lox) (22) were on a BALB/c background.
Mice were housed in specific-pathogen-free conditions at
Glasgow University, UK, and Cape Town University, South
Africa, in accordance with animal experimentation guidelines.
IL-33 treatment in vivo
Recombinant IL-33 was prepared as described (23). Mice
were injected i.p. with IL-33 (2 lg/mouse) or PBS daily for
1–7 days unless stated otherwise. Cells were collected by peri-
toneal washout with 2 ml of cold PBS.
Anaphylaxis (AS): Mice were injected i.p. with IL-33 (2 lg)
or PBS daily for 3–4 days. Changes in clinical signs and temper-
ature were monitored every 10 min after each injection, using a
rectal probe (Natsume Seisakusyo Co., Tokyo, Japan). Plasma
histamine was measured by ELISA (IBL, Hamburg, Germany).
Flow cytometry
Cells (3 9 105 cells/tube) were stained with fluorochrome-
conjugated antibodies anti-CD3, anti-CD4, anti-CD19, anti-
FceRI, anti-CD40L, anti-CD25, anti-CD117 and Siglec-F
and isotype controls (BD Bioscience, Oxford, UK). Intracel-
lular cytokine levels in peritoneal cells were determined by
staining with anti-IL-4-PE after activation (PMA/ionomycin)
and permeabilization. Cells were analysed by FACSCalibur
using Cell Quest software (BD Bioscience).
Cytokine and IgE measurements
Serum concentrations of cytokines were determined by
Luminex (Luminex, Biosource; Invitrogen, Life Technologies
Ltd, Paisley, UK) and IgE by ELISA (Bethyl Laboratories,
Inc, Montgomery, TX, USA).
Histological analysis of mast cells
Skin samples were stained with toluidine blue to identify and
count mast cells by microscopy. Degranulated mast cells were
identified as those with >10% extrusion of granules (20).
Statistical analysis
Student’s t-test was applied to in vitro studies. Analysis
between individuals in groups in vivo was carried out by
ANOVA followed by Student’s t-test.
Results
IL-33-induced IgE but not type-II cytokines is IL-4
dependent
Mice had seven daily injections of IL-33 or PBS. Low basal
concentrations of serum IgE, IL-4 and IL-13 were main-
tained in antigen-naı¨ve or PBS-treated mice, but were signifi-
cantly elevated in wild-type (WT), but not ST2/ mice,
within 3 days of IL-33 administration (Fig. 1A,B) IL-4 pro-
duction preceded the increase in IgE. As reported (9), IL-33
did not induce IFN-c in naı¨ve WT mice (data not shown).
These results suggest that IL-33 is a powerful and rapid
inducer of IgE in naı¨ve mice that might be mediated by type-
II cytokines.
IL-4 in mice and IL-4 and IL-13 in humans are key
cytokines for the initiation of type-II responses and IgE
isotype class switching (4, 24). We therefore determined the
role of IL-4 and IL-13 in IL-33-induced IgE synthesis. WT
and IL-4Ra/ mice were injected with IL-33 resulting in
higher serum concentrations of IL-4 and IL-13 in IL-4Ra/
mice compared with PBS-treated IL-4Ra/ mice or with IL-
33-treated WT mice (Fig. 1C), probably due to reduced
sequestration of these cytokines in the absence of IL-4Ra
(25). More importantly, IL-33 failed to enhance IgE in
IL-4Ra/ mice (Fig. 1C). Together, these data indicate that
IL-33-mediated induction of IgE is dependent on IL-4Ra
responsiveness and that IL-4/IL-13 induction is not.
Because IL-4Ra deficiency abolishes both IL-4 and IL-13
functions (21, 22), we assessed the requirement of IL-4 for
IgE production using IL-4/ mice. WT and IL-4/
mice were injected with IL-33. IL-33 induced similar levels
of IL-13 production in the WT and IL-4/ mice (Fig. 1D),
but IL-33 failed to enhance IgE in IL-4/ mice (Fig. 1D).
Thus, IL-4 is necessary and sufficient for the induction of
IgE by IL-33 in naı¨ve mice.
IL-33 induces type-II cytokines mainly via innate cells in
naı¨ve mice
We next investigated whether the increased IL-4 and IL-13
levels in IL-33-treated mice were produced by T cells or
innate cells in vivo by comparing WT and athymic nude mice
(lacking T cells) injected with IL-33 or PBS as described
above. Nude mice produced significantly higher levels of
serum IL-4 and IL-13 than IL-33-treated WT mice, but
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markedly lower IgE (Fig. 2A). This suggests two points. First,
T cells have minimal contribution to IL-33-induced type-II
cytokine production in vivo. Second, while IL-33 could induce
significant amounts of IgE in nude mice compared with PBS
control, the levels of IgE were markedly lower than those of
IL-33 in WT mice, suggesting that T cells have a modest but
significant role in IL-33-mediated IgE induction, independent
of enhanced type-II cytokine synthesis.
We next determined which were the IL-4-producing cells
in vivo from IL-33- or PBS-treated WT mice by flow cytome-
try. IL-33 enhanced the IL-4 expression in CD117 (c-Kit)+
mast cells (11% compared with 1% in PBS-treated controls)
and in Siglec-F+ eosinophils (31% compared with 2% in
PBS controls) (Fig. 2B). However, IL-33 failed to increase
the frequency of IL-4+ CD4+ T cells (Fig. 2B). IL-33 also
increased the numbers of total cells, mast cells, eosinophils
and to a lesser extent CD4+ T cells in the peritoneal cavity
(Fig. 2C). Thus, IL-33 mainly induces type-II cytokines via
innate immune cells in naı¨ve mice.
B cells expressing the IL-4Ra are required for IL-33-induced
B-cell expansion and IgE production in vivo
We have previously shown that conventional CD19+ B cells
do not express ST2 (26), suggesting that IL-33 may only
induce IgE synthesis indirectly, likely via IL-4 as we have
demonstrated earlier. We therefore assessed the role of
IL-4Ra signalling on B cells in IL-33-induced IgE synthesis
by comparing naı¨ve B-cell-specific IL-4Ra/ (selectively
deleted of IL-4Ra on B cells), IL-4Ra/ (total IL-4Ra dele-
tion) and WT mice treated with IL-33 or PBS. IL-33 induced
IgE synthesis in WT but not in IL-4Ra/ or B-IL-4Ra/
mice (Fig. 3A). Serum IL-4 and IL-13 concentrations in
B-IL-4Ra/ and WT mice were similar but were signifi-
cantly lower than those of the IL-4Ra/ mice (Fig. 3B),
suggesting that cells other than B cells may consume some of
these cytokines. IL-33 increased the total cell number and the
number of CD19+ B cells (but not CD4+ T cells) in the
spleen of WT mice but not in IL-4Ra/ or B-IL-4Ra/
mice (Fig. 3C). Because IL-13 does not directly induce IgE in
mouse B cells (24), together these results suggest that IL-33
indirectly elicits natural IgE production in naı¨ve mice by
inducing IL-4, which then directly stimulates B-cell expansion
and IgE isotype class switching.
T cells expressing IL-4Ra contribute to IL-33-induced IgE
synthesis
Our aforementioned results (Fig. 2A,B) suggest that T cells
also contribute to IL-33-enhanced IgE production in naı¨ve
mice other than by providing type-II cytokines. To assess the
potential role of IL-4R responses by T cells, we injected
A 
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Figure 1 IL-33 induces IgE but not type-II cytokine production in an
IL-4-dependentmanner. Groups ofwild-type (A), ST2/ (B), IL-4Ra/
(C) and IL-4/ (D) micewere injected i.p. with IL-33 (2 lg) or PBS daily
for 7 days. Total serum IgE, IL-4 and IL-13 concentrations were mea-
sured by ELISA. Data are representative of three experiments, n = 5–
7mice per group, *P < 0.05, **P < 0.01 compared to PBS controls.
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IL-33 or PBS into WT or T-IL4Ra/ (LckcreIl4ra/lox mice,
selectively deleted of IL-4Ra on T cells) mice. IL-33 modestly
but significantly increased serum IgE levels in T-IL-4Ra/
mice (Fig. 4A). Consistent with the result from nude mice
(Fig. 2A), IL-33 elicited abundantly increased level of IL-4
and IL-13 in T-IL4Ra/ compared with WT mice (Fig. 4B),
suggesting that these cytokines are unlikely to play an impor-
tant role in T-cell function in IL-33-induced IgE production.
An alternative contribution therefore should be considered.
CD40L expression on T cells is required for B cells to pro-
duce IgE, and the expression of CD40L on T cells can be
enhanced by IL-2 receptor signals (3, 27). We therefore
assessed whether IL-33 could up-regulate the expression of
CD40L and CD25 (IL-2 receptor a chain) on T cells.
Because murine CD4+ T cells only respond to IL-4 but not
IL-13 (because of the lack of IL-13 receptor) (24), we
examined IL-33-mediated T-cell function in IL-4/ mice ex
vivo. IL-33 increased the surface expression of CD40L and
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CD25 on CD4+ T cells in WT mice but not in IL-4/ mice
(Fig. 4C). Consistent with our finding (Fig. 3C), IL-33 also
increased the total number of B cells (but not T cells) in the
WT but not in IL-4/ mice (Fig. 4D). Thus, IL-33
stimulates CD40L and CD25 expression on T cells via IL-4,
which may contribute to the IL-33-induced IgE production
in naı¨ve mice.
IL-33 triggers mast cell degranulation in WT but not ST2/
or IL4Ra/ mice
Because natural IgE can bind to mast cell FceRI and impact
mast cell functions (5–7), we sought to investigate what effect
IL-33 and IL-33-derived IgE may have on mast cell function
in naı¨ve mice.
Naı¨ve WT, ST2/ or IL4Ra/ mice were injected with
IL-33 or PBS daily for up to 3 days. IL-33 treatment
markedly increased the mast cell surface IgE in naı¨ve WT
but not in IL4Ra/ mice as evidenced by enhanced levels of
membrane-bound IgE and reduced levels of unoccupied
FceRI on mast cells (Fig. 5A). IL-33 treatment enhanced
total and degranulated skin mast cells compared with PBS
controls in WT but not ST2/ or IL4Ra/ mice (Fig. 5B).
More importantly, 30 min after the third IL-33 challenge,
WT but not ST2/ or IL4Ra/ mice showed clear signs of
shock (piloerection, prostration, reduced response to stimuli),
with a rapid reduction in body temperature lasting for about
15 min before returning to normal (Fig. 5C), and a substan-
tial increase in serum histamine levels (Fig. 5D). Together,
these results demonstrate that IL-33 can initiate mast cell
degranulation and systemic anaphylaxis in naı¨ve mice via
IL4Ra.
Discussion
Data reported in this study reveal a hitherto unrecognized
effect and mechanism by which IL-33 induces IgE production
and anaphylaxis in the absence of specific allergen (Fig. 6).
IL-33 triggers IL-4 secretion by innate cells, which then
stimulates B-cell expansion and IgE synthesis. In parallel,
IL-4 enhances T-cell expression of CD40L, which interacts
with CD40 on B cells to complement IgE production. IL-33
and IgE then synergistically trigger mast cell degranulation
and anaphylaxis. Thus, IL-4 is the key intermediate in
IL-33-mediated anaphylaxis in vivo. Because the mice were
allergen naı¨ve and we found that serum samples even from 7
daily injections of IL-33, which showed enhanced levels of
total IgE, failed to show any detectable recombinant IL-
33-specific IgE (data not shown) by ELISA (Data S1), it is
likely, although not proven, that this IgE is natural IgE as
described previously (3).
We demonstrated here that eosinophils and mast cells can
produce IL-4 upon IL-33 treatment in naı¨ve mice. However, it
is likely that other ST2+ innate cells such as basophils and
NKT cells can similarly produce IL-4 (10, 14, 16). By contrast,
T cells, which are the key cells expressing type-II cytokines in
allergy, are not the major IL-4 producers in this innate immune
context. This may be because naı¨ve T cells do not express ST2
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and hence are not responsive to IL-33 in the absence of T cell
receptor activation (17, 18). In addition, it is known that IL-33
induces mainly IL-5 but not IL-4 in activated T cells and there-
fore cannot polarize Th2 cells (17).
Using nude mice and T-IL-4Ra-deficient mice, we demon-
strated that T cells nevertheless play a significant role in
IL-33-derived IgE production in naı¨ve mice. However, this
process is unlikely to involve IL-4 production, because nude
mice and T-IL-4Ra-deficient mice produced normal or
elevated levels of IL-4 and yet had significantly less IgE
compared to WT mice. Previous studies have shown that T
cells expressing CD40L are required for the induction of
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natural IgE and that the CD40L expression can be enhanced
by IL-2 (3, 27). Furthermore, IL-33 can induce IL-2 produc-
tion in T cells (10). We show here that IL-33 can increase
CD40L and CD25 expression on CD4+ T cells via IL-4. It is
therefore likely that IL-33-derived IL-4 and IL-2, alone or
together, stimulate CD4+ T cells to express surface CD40L,
which subsequently interacts with B cells to promote IgE
production.
Anaphylaxis (AS) is an acute, life-threatening allergic
reaction in which IgE-mediated mast cell degranulation plays
a critical role (28, 29). The aetiology of AS in particular
idiopathic AS is not fully understood (28, 30). Our result
demonstrated for the first time that IL-33/ST2 signals can
trigger anaphylaxis in naı¨ve mice in the absence of specific
allergen (Fig. 5). While the detailed molecular mechanism is
still unresolved, we found the IL-33-mediated allergen-inde-
pendent mast cell degranulation and systemic AS described
here was dependent on ST2, IL-4Ra and required repeated
IL-33 stimulation (Fig. 5C). Thus, the mechanism may
comprise a combination of the following two components:
1 It is known that increased mast cell surface IgE expres-
sion and mast cell activation are the hallmark of mast
cell degranulation and AS. We found that IL-33 can
markedly enhance the levels of serum and mast cell
surface IgE that is dependent on ST2 and IL-4Ra in
antigen-naı¨ve mice. In addition, mast cells also express
high levels of ST2, IL-4Ra and IgE FceR, and it is
known that signals via these receptors play critical roles
in mast cell activation and function. IL-33 can directly
stimulate mast cell proliferation, cytokine production and
activation (Fig. 2B, C and ref. 19), and the signals from
the interaction between IL-4/IL-13 and IgE with their
receptors can activate and prolong the survival of mast
cells as well as can exacerbate AS (6, 8, 31).
2 We also found that at least three daily IL-33 treatments
were required for IL-33 to trigger mast cell degranulation
and AS. Intriguingly, this was also the critical time
required for IL-33 to elicit significant production of IgE
and IL-4/IL-13 and mast cell proliferation (Figs 1A, 2B,C
and 5).
Thus, our results suggest that while IL-33, IL-4 or IgE alone
is insufficient to trigger mast cell degranulation without aller-
gen, the accumulated number and activation status of mast
cells, strong FceR signals derived from continued and inten-
sive interaction between IgE and its high-affinity receptor
and repetitive IL-33/ST2 and IL-4Ra signals may cumula-
tively or synergistically reach a signal threshold that leads to
mast cell degranulation and AS.
IL-33 is clearly detected in various clinical allergic dis-
eases including asthma and dermatitis (15, 32, 33). Given
that many allergic reactions occur without a known aller-
gen, including nonatopic asthma and idiopathic anaphylaxis
(30, 34), IL-33 may play a critical role in these diseases.
Supporting this hypothesis, we have measured serum IL-33
levels in atopic and nonatopic patients with severe asthma
by ELISA. Our results showed that asthma subjects have a
wide range of serum IL-33 levels and that there was no sig-
nificant difference between atopic and nonatopic subjects
(Fig. S1). This result is consistent with our finding in the
animal model, as well as with a recent report that IL33
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Figure 6 Schematic representation of the mechanism of IL-33-
induced IgE synthesis and anaphylaxis in naive mice. IL-33 bind-
ing to ST2+ innate cells, such as mast cells and eosinophils,
leads to mast cell proliferation and increased IL-4 synthesis. IL-4
would then activate B cells to proliferate and to produce IgE. IL-4
produced by the innate cells could also activate T cells to
express CD40L that interacts with CD40 on B cells to
further enhance IgE production. IgE, together with IL-33 and IL-4,
would stimulate mast cells to degranulate, resulting in
anaphylaxis.
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polymorphism is correlated with clinical asthma but not
necessarily atopy (35).
Because IL-4 and IL-13 also play a pivotal role in antigen-
specific IgE production, IL-33 may therefore have a general
effect on all IgE-mediated allergic conditions. This concept
suggests that IL-33 may represent a novel therapeutic target
for a range of allergic diseases.
Disclosures
The authors have no financial conflicts of interest.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Serum IL-33 levels are not associated with
atopy.
Data S1. Methods.
Please note: Wiley-Blackwell are not responsible for the con-
tent or functionality of any supporting materials supplied by
the authors. Any queries (other than missing material) should
be directed to the corresponding author for the article.
References
1. Gould HJ, Sutton BJ. IgE in allergy and
asthma today. Nat Rev Immunol 2008;67:
205–217.
2. Vercelli D, Jabara HH, Arai K, Geha RS.
Induction of human IgE synthesis requires
interleukin 4 and T/B cell interactions
involving the T cell receptor/CD3 complex
and MHC class II antigens. J Exp Med
1989;169:1295–1307.
3. McCoy KD, Harris NL, Diener P, Hatak S,
Odermatt B, Hangartner L et al. Natural IgE
production in the absence of MHC Class II
cognate help. Immunity 2006;24:329–339.
4. Finkelman FD, Holmes J, Katona IM,
Urban JF Jr, Beckmann MP, Park LS et al.
Lymphokine control of in vivo immunoglob-
ulin isotype selection. Annu Rev Immunol
1990;8:303–333.
5. Asai K, Kitaura J, Kawakami Y, Yamagata
N, Tsai M, Carbone DP et al. Regulation of
mast cell survival by IgE. Immunity
2001;14:791–800.
6. Kalesnikoff J, Huber M, Lam V, Damen JE,
Zhang J, Siraganian RP et al. Monomeric
IgE stimulates signaling pathways in mast
cells that lead to cytokine production and
cell survival. Immunity 2001;14:801–811.
7. Bryce PJ, Miller ML, Miyajima I, Tsai M,
Galli SJ, Oettgen HC. Immune sensitization
in the skin is enhanced by antigen-indepen-
dent effects of IgE. Immunity 2004;20:
381–392.
8. Galli SJ, Kalesnikoff J, Grimbaldeston MA,
Piliponsky AM, Williams CM, Tsai M. Mast
cells as “tunable” effector and immunoregu-
latory cells: recent advances. Annu Rev
Immunol 2005;23:749–786.
9. Schmitz J, Owyang A, Oldham E, Song Y,
Murphy E, McClanahan TK et al. IL-33, an
interleukin-1-like cytokine that signals via
the IL-1 receptor-related protein ST2 and
induces T helper type 2-associated cytokines.
Immunity 2005;23:479–490.
10. Ali S, Huber M, Kollewe C, Bischoff SC,
Falk W, Martin MU. IL-1 receptor accessory
protein is essential for IL-33-induced activa-
tion of T lymphocytes and mast cells. Proc
Natl Acad Sci U S A 2007;104:18660–18665.
11. Luthi AU, Cullen SP, McNeela EA, Duriez
PJ, Afonina IS, Sheridan C et al. Suppres-
sion of interleukin-33 bioactivity through
proteolysis by apoptotic caspases. Immunity
2009;31:84–98.
12. Trajkovic V, Sweet MJ, Xu D. T1/ST2–an
IL-1 receptor-like modulator of immune
responses. Cytokine Growth Factor Rev
2004;15:87–95.
13. Oboki K, Ohno T, Kajiwara N, Arae K,
Morita H, Ishii A et al. IL-33 is a crucial
amplifier of innate rather than acquired
immunity. Proc Natl Acad Sci U S A
2010;107:18581–18586.
14. Pecaric-Petkovic T, Didichenko SA,
Kaempfer S, Spiegl N, Dahinden CA.
Human basophils and eosinophils are the
direct target leukocytes of the novel IL-1
family member IL-33. Blood 2009;113:
1526–1534.
15. Kurowska-Stolarska M, Stolarski B, Kewin
P, Murphy G, Corrigan CJ, Ying S et al.
IL-33 amplifies the polarization of alterna-
tively activated macrophages that contribute
to airway inflammation. J Immunol
2009;183:6469–6477.
16. Smithgall MD, Comeau MR, Yoon BR,
Kaufman D, Armitage R, Smith DE. IL-33
amplifies both Th1- and Th2-type responses
through its activity on human basophils,
allergen-reactive Th2 cells, iNKT and NK
cells. Int Immunol 2008;20:1019–1030.
17. Kurowska-Stolarska M, Kewin P, Murphy
G, Russo RC, Stolarski B, Garcia CC et al.
IL-33 induces antigen-specific IL-5 + T cells
and promotes allergic-induced airway
inflammation independent of IL-4. J Immu-
nol 2008;181:4780–4790.
18. Xu D, Chan WL, Leung BP, Huang F,
Wheeler R, Piedrafita D et al. Selective
expression of a stable cell surface molecule
on type 2 but not type 1 helper T cells. J
Exp Med 1998;187:787–794.
19. Xu D, Jiang HR, Kewin P, Li Y, Mu R,
Fraser AR et al. IL-33 exacerbates antigen-
induced arthritis by activating mast cells.
Proc Natl Acad Sci U S A 2008;105:
10913–10918.
20. Xu D, Jiang HR, Li Y, Pushparaj PN,
Kurowska-Stolarska M, Leung BP et al.
IL-33 exacerbates autoantibody-induced
arthritis. J Immunol 2010;184:
2620–2626.
21. Mohrs M, Ledermann B, Kohler G,
Dorfmuller A, Gessner A, Brombacher F.
Differences between IL-4- and IL-4 receptor
alpha-deficient mice in chronic leishmaniasis
reveal a protective role for IL-13 receptor
signaling. J Immunol 1999;162:
7302–7308.
22. Radwanska M, Cutler AJ, Hoving JC,
Magez S, Holscher C, Bohms A et al. Dele-
tion of IL-4Ralpha on CD4 T cells renders
BALB/c mice resistant to Leishmania major
infection. PLoS Pathog 2007;3:e68.
23. Miller AM, Xu D, Asquith DL, Denby L,
Li Y, Sattar N et al. IL-33 reduces the devel-
opment of atherosclerosis. J Exp Med
2008;205:339–346.
24. Zurawski G, de Vries JE. Interleukin 13, an
interleukin 4-like cytokine that acts on
monocytes and B cells, but not on T cells.
Immunol Today 1994;15:19–26.
25. Brewer JM, Conacher M, Hunter CA, Mo-
hrs M, Brombacher F, Alexander J. Alumin-
ium hydroxide adjuvant initiates strong
antigen-specific Th2 responses in the absence
of IL-4- or IL-13-mediated signaling. J
Immunol 1999;163:6448–6454.
26. Komai-Koma M, Gilchrist DS, McKenzie
AN, Goodyear CS, Xu D, Liew FY. IL-33
activates B1 cells and exacerbates
contact sensitivity. J Immunol
2011;186:2584–2591.
27. Yoshimoto T, Min B, Sugimoto T, Hayashi
N, Ishikawa Y, Sasaki Y et al. Nonredun-
dant roles for CD1d-restricted natural killer
T cells and conventional CD4 + T cells in
the induction of immunoglobulin E antibod-
ies in response to interleukin 18 treatment of
mice. J Exp Med 2003;197:997–1005.
28. Golden DB. What is anaphylaxis? Curr Opin
Allergy Clin Immunol 2007;7:331–336.
29. Metcalfe DD, Peavy RD, Gilfillan AM.
Mechanisms of mast cell signaling in
Allergy 67 (2012) 1118–1126 © 2012 John Wiley & Sons A/S 1125
Komai-Koma et al. IL-33 and IgE
anaphylaxis. J Allergy Clin Immunol
2009;124: quiz 639–646.
30. Lenchner K, Grammer LC. A current review
of idiopathic anaphylaxis. Curr Opin Allergy
Clin Immunol 2003;3:305–311.
31. Strait RT, Morris SC, Smiley K, Urban JF
Jr, Finkelman FD. IL-4 exacerbates
anaphylaxis. J Immunol 2003;170:
3835–3842.
32. Sakashita M, Yoshimoto T, Hirota T,
Harada M, Okubo K, Osawa Y et al. Asso-
ciation of serum interleukin-33 level and the
interleukin-33 genetic variant with Japanese
cedar pollinosis. Clin Exp Allergy
2008;38:1875–1881.
33. Shimizu M, Matsuda A, Yanagisawa K,
Hirota T, Akahoshi M, Inomata N et al.
Functional SNPs in the distal promoter of
the ST2 gene are associated with atopic
dermatitis. Hum Mol Genet 2005;14:
2919–2927.
34. Pearce N, Pekkanen J, Beasley R. How
much asthma is really attributable to atopy?
Thorax 1999;54:268–272.
35. Moffatt MF, Gut IG, Demenais F, Strachan
DP, Bouzigon E, Heath S et al. A large-
scale, consortium-based genomewide associa-
tion study of asthma. N Engl J Med
2010;363:1211–1221.
Allergy 67 (2012) 1118–1126 © 2012 John Wiley & Sons A/S1126
IL-33 and IgE Komai-Koma et al.
